Halvorsen R A, Magruder-Habib K, Foster W L, Roberts L, Postlethwait R W, Thompson W M
Radiology. 1986 Oct;161(1):147-51. doi: 10.1148/radiology.161.1.3763857.
To evaluate the utility of computed tomographic (CT) staging in patients with esophageal cancer, the length of patient survival was compared with pretherapy CT findings in 89 patients. Regardless of therapy, patients with evidence of mediastinal invasion, liver metastases, or abdominal adenopathy had a statistically shortened survival (P less than .05). Specific CT criteria that predicted a shortened survival included evidence of tracheal, aortic, or pericardial invasion. Patients with evidence of both mediastinal invasion and abdominal metastases had a mean survival of 180.4 days; those with no evidence, 479.6 days. The presence of enlarged upper abdominal lymph nodes indicated the worst prognosis (mean survival, 90 days). The patients with squamous cell tumors were classified by the CT staging system, and survival data were compared according to surgical procedure. Patients who underwent attempted curative surgery did not have a statistically significant difference in survival by analysis of survival curves but demonstrated a longer mean survival than those who underwent palliative or no surgery.
为评估计算机断层扫描（CT）分期在食管癌患者中的应用价值，对89例患者的生存时长与治疗前CT检查结果进行了比较。无论采用何种治疗方法，有纵隔侵犯、肝转移或腹部淋巴结病证据的患者，其生存期在统计学上均缩短（P<0.05）。预测生存期缩短的具体CT标准包括气管、主动脉或心包侵犯的证据。有纵隔侵犯和腹部转移证据的患者平均生存期为180.4天；无上述证据的患者为479.6天。上腹部淋巴结肿大提示预后最差（平均生存期90天）。对鳞状细胞肿瘤患者采用CT分期系统进行分类，并根据手术方式比较生存数据。通过生存曲线分析，接受根治性手术尝试的患者生存期无统计学显著差异，但平均生存期长于接受姑息性手术或未手术的患者。
